The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis-Reference-Cited by-同舟云学术

The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis

Published:2019-01 Issue: Volume:122 Page:188-197
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

van der Graaff D.,Kwanten W.J.,Francque S.M.

Funder

FWO

Publisher

Elsevier BV

Subject

General Medicine

Reference138 articles.

1. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;EASL;J Hepatol,2016

2. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis;Targher;J Hepatol,2016

3. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications;Francque;J Hepatol,2016

4. Pathophysiology and mechanisms of nonalcoholic fatty liver disease;Haas;Annu Rev Physiol,2016

5. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe;Younossi;Hepatology,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endotoxin Inflammatory Action on Cells by Dysregulated-Immunological-Barrier-Linked ROS-Apoptosis Mechanisms in Gut–Liver Axis;International Journal of Molecular Sciences;2024-02-20

2. The liver sinusoid in chronic liver disease: NAFLD and NASH;Sinusoidal Cells in Liver Diseases;2024

3. The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease;International Journal of Obesity;2023-12-23

4. Exploration of the Shared Gene and Molecular Mechanisms between Breast Cancer and Non-alcoholic Fatty Liver Disease Based on Available Public Transcriptome Sequencing Data;2023-09-12

5. The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression;Nano Letters;2023-05-08